Showing results (11-20 of 28) with videos related to
Sort By:
Pageof 3
Leukemia|January 10, 2014
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisonsA Tefferi, T L Lasho, C M Finke, et al.Leukemia|October 29, 2011
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patientsM M Patnaik, C A Hanson, J M Hodnefield, et al.Leukemia|May 6, 2014
Calreticulin mutations and long-term survival in essential thrombocythemiaA Tefferi, E A Wassie, T L Lasho, et al.Leukemia|April 4, 2014
ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patientsM M Patnaik, R Itzykson, T L Lasho, et al.Leukemia|April 23, 2013
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemiaA Pardanani, T L Lasho, R R Laborde, et al.Leukemia|October 23, 2009
JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survivalA Tefferi, T L Lasho, M M Patnaik, et al.Leukemia|March 6, 2013
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosisA Pardanani, R R Laborde, T L Lasho, et al.Leukemia|March 6, 2009
Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlatesA Tefferi, R L Levine, K-H Lim, et al.Leukemia|February 6, 2014
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patientsA Tefferi, P Guglielmelli, T L Lasho, et al.Blood Cancer Journal|January 3, 2015
Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcomeM M Patnaik, E A Wassie, E Padron, et al.Pageof 3